Supplementary material

Mihajlović M, Marinković M, Kozieł M, et al. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention. Kardiol Pol. 2020; 78: 512-519. doi:10.33963/KP.15428

Table S1. The WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS and ENTRUST-AF PCI trials safety end-point event rates.

	WOEST[1]		**PIONEER AF-PCI[2]**			**RE-DUAL PCI[3]**			**AUGUSTUS[4]**				**ENTRUST-AF PCI[5]**	
	DAT n (%)	**TAT n (%)**	**Riv 15mg, n (%)**	**Riv 2.5 mg, n (%)**	**TAT, n (%)**	**Dab 110mg, n (%)**	**Dab 150mg, n (%)**	**TAT, n (%)**	**Api vs VKA, n (%)**		**ASA vs Placebo, n (%)**		**Edo, n (%)**	**TAT, n (%)**
Trial defined safety end point*	54 (19.4)	126 (44.4)	109 (16.8)	117 (18.0)	167 (26.7)	151 (15.4)	154 (20.2)	264 (26.9)	241 (10.5)	332 (14.7)	367 (16.1)	204 (9.0)	128 (17.0)	152 (20.1)
TIMI major	39	89	109	117	167	29	27	69	96	132	146	80	NR	NR

and minor bleeding	(14.0)	(31.3)	(16.8)	(18.0)	(26.7)	(3.0)	(3.5)	(7.0)	(4.2)	(5.8)	(6.4)	(3.5)		
ISTH Major or CRNM bleeding	NR	NR	117 (16.8)	122 (17.3)	239 (17.0)	151 (15.4)	154 (20.2)	264 (26.9)	241 (10.5)	332 (14.7)	367 (16.1)	204 (9.0)	128 (17.0)	152 (20.1)
ISTH Major bleeding	NR	NR	27 (3.9)	25 (3.5)	48 (6.9)	49 (5.0)	43 (5.6)	90 (9.2)	69 (3.0)	104 (4.6)	108 (4.7)	65 (2.9)	45 (6.0)	48 (6.4)
ISTH CRNM bleeding	NR	NR	90 (12.9)	97 (13.7)	130 (18.7)	102 (10.4)	111 (14.6)	174 (17.7)	180 (7.9)	246 (10.9)	275 (12.1)	148 (6.5)	97 (12.9)	114 (15.1)
intracranial haemorrhage	3 (1.1)	3 (1.1)	NR	NR	NR	3 (0.3)	1 (0.1)	10 (1.0)	5 (0.2)	13 (0.6)	8 (0.4)	10 (0.4)	4 (0.5)	9 (1.2)

AF, atrial fibrillation; **PCI,** percutaneous coronary intervention; **DAT,** dual antithrombotic therapy; **TAT,** triple antithrombotic therapy; **Riv,** rivaroxaban; **Dab,** dabigatran; **Api,** apixaban; **Edo,** edoxaban; **TIMI,** thrombolysis in myocardial Infarction; **ISTH,** international society on thrombosis and haemostasis; **CRNM,** clinically relevant nonmajor; **NR,** not reported.

*Trials defined safety end-points are shown in Table 1.

Table S2. The WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS and ENTRUST-AF PCI trials efficacy end-point event rates.

	WOEST[1]		**PIONEER AF-PCI[2]**			**RE-DUAL PCI[3]**			**AUGUSTUS[4]**				**ENTRUST-AF PCI[5]**	
	DAT, n (%)	**TAT, n (%)**	**Riv 15 mg, n (%)**	**Riv 2.5 mg, n (%)**	**TAT, n (%)**	**Dab 110 mg, n (%)**	**Dab 150 mg, n (%)**	**TAT, n (%)**	**Api vs VKA, n (%)**		**ASA vs Placebo, n (%)**		**Edo, n (%)**	**TAT, n (%)**
Trial defined MACE*	31 (11.1)	50 (17.6)	41 (6.5)	36 (5.6)	36 (6.0)	149 (15.2)	90 (11.8)	131 (13.4)	154 (6.7)	163 (7.1)	149 (6.5)	168 (7.3)	49 (7%)	46 (6%)
All-cause death	7 (2.5)	18 (6.3)	NR	NR	NR	55 (5.6)	30 (3.9)	48(4.9)	77 (3.3)	74 (3.2)	72 (3.1)	79 (3.4)	46 (6.1)	37 (4.9)
CV deaths	3 (1.1)	7 (2.5)	15 (2.4)	14 (2.2)	11 (1.9)	NR	NR	NR	57 (2.5)	54 (2.3)	53 (2.3)	58 (2.5)	17 (2.3)	16 (2.1)

Myocardial infarction	9 (3.2)	13 (4.6)	19 (3.0)	17 (2.7)	21 (3.5)	44 (4.5)	26 (3.4)	29 (3.0)	72 (3.1)	80 (3.5)	68 (2.9)	84 (3.6)	29 (3.9)	23 (3.0)
Stent thrombosis	4 (1.4)	9 (3.2)	5 (0.8)	6 (0.9)	4 (0.7)	15 (1.5)	7 (0.9)	8 (0.8)	14 (0.6)	18 (0.8)	11 (0.5)	21 (0.9)	8 (1.1)	6 (0.8)
Stroke	3 (1.1)	8 (2.8)	8 (1.3)	10 (1.5)	7 (1.2)	17 (1.7)	9 (1.2)	13 (1.3)	13 (0.6)	26 (1.1)	20 (0.9)	19 (0.8)	10 (1.3)	12 (1.6)

AF, atrial fibrillation; **PCI,** percutaneous coronary intervention; **DAT,** dual antithrombotic therapy; **TAT,** triple antithrombotic therapy; **Riv,** rivaroxaban; **Dab,** dabigatran; **Api,** apixaban; **Edo,** edoxaban; **MACE,** major adverse cardiac events: **CV,** cardiovascular; **NR,** not reported.

*Trials defined MACE are shown in Table 1.

References

1. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381: 1107-1115.

2. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375: 2423-2434.

3. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377: 1513-1524.

4. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019; 380: 1509-1524.

5. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394: 1335-1343.